United States: US FDA Advisory Committee Backs Gene Therapy For Rare Form Of Blindness – Mondaq News Alerts
|
United States: US FDA Advisory Committee Backs Gene Therapy For Rare Form Of Blindness
Mondaq News Alerts On October 12, 2017, the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue and Gene Therapies Advisory Committee has paved the way for the agency’s first approval of a gene therapy to treat a disease caused by a genetic mutation. A panel of … |
News-Medical.net |
Gene therapy shows promising effect against blood clots, study states
News-Medical.net A new study conducted in the Children’s Hospital Of Philadelphia (CHOP) reported positive results in a phase 1/2 clinical trial for the inherited bleeding disorder hemophilia B. Credit: Sebastian Kaulitzki/ Shutterstock.com. A single blood vessel … Gene therapy shows promise against blood-clotting disease …Borneo Bulletin Online Gene Therapy Shows Promise in Factor IX Coagulant Activity for …Monthly Prescribing Reference |
News-Medical.net |
Gene therapy shows promising effect against blood clots, study states
News-Medical.net A new study conducted in the Children’s Hospital Of Philadelphia (CHOP) reported positive results in a phase 1/2 clinical trial for the inherited bleeding disorder hemophilia B. Credit: Sebastian Kaulitzki/ Shutterstock.com. A single blood vessel … Gene therapy shows promise against blood-clotting disease …Borneo Bulletin Online Gene Therapy Shows Promise in Factor IX Coagulant Activity for …Monthly Prescribing Reference |
CBC.ca |
‘Wow, it’s actually beating’: Novoheart creates tiny heart-like structure with stem cells to test new drugs
CBC.ca Beating rhythmically and suspended in a jar, tiny heart-like structures made from stem cells are the latest innovation for drug testing — technology that has the potential to save pharmaceutical companies money. They’re developed by Canadian-backed … |
FierceBiotech |
Gilead makes bolt-on CAR–T buy after Kite deal
FierceBiotech This is also not a huge surprise given Kite already had a collaboration with Cell Design from June 2016 based on Kite’s strategy to already build precision-controlled CAR products that can be turned ‘on or off’.” It added that investors “should expect … Gilead swoops in with $567M deal to buy CAR–T 2.0 player Cell Design LabsEndpoints News Gilead, Kite to Acquire Cell Design Labs for Up-to-$567M, Growing CAR–T FootprintGenetic Engineering & Biotechnology News Gilead deepens CAR–T push with deal for Cell DesignBioPharma Dive Xconomy –BioPharma-Reporter.com –Business Wire (press release) all 49 news articles » |